Interní Med. 2012; 14(11): 429-431

Uncommon complication of primary aldosteronism

doc.MUDr.Robert Holaj, CSc., MBA1, MUDr.Branislav Štrauch, Ph.D.1, MUDr.Jaroslav Hlubocký, Ph.D.2, prof.MUDr.Jiří Widimský jr., CSc.1
1 3. interní klinika, klinika endokrinologie a metabolizmu
2 Klinika kardiovaskulární chirurgie Všeobecné fakultní nemocnice a 1. lékařské fakulty UK v Praze

The primary aldosteronism is a frequent cause of secondary hypertension and its diagnosis should be considered in all patients with

moderate to severe hypertension where low potassium level was found. Cardiovascular complications occurre more often in these patients

in comparison those with the essential hypertension. The authors present a case of an annulo-aortic ectasia and the small dorsal wall

chronic aortic roof dissection in 56-years old man with the primary aldosteronism and severe hypertension. The patient underwent successful

cardiosurgery. The aortic roof remodelling and aortic valve plasty was performed. Nevertheless, the ascending aorta impairment

in patients with primary aldosteronism is a rare complication. The case should notice on possibility of this frequent form of secondary

hypertension and encourage us to increase our effort in the active search for the patients with the primary aldosteronism. That should be

our regular contribution to the reduction of the incidence of the late cardiovascular complications through appropriate treatment strategy.

Keywords: primary aldosteronism, annulo-aortic ectasia, aortic dissection

Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Holaj R, Štrauch B, Hlubocký J, Widimský J. Uncommon complication of primary aldosteronism. Interní Med. 2012;14(11):429-431.
Download citation

References

  1. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronizm, including surgically correctable forms, in centers from five continents. The Journal of clinical endocrinology and metabolism 2004; 89: 1045-1050. Go to original source... Go to PubMed...
  2. Štrauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J, Jr. Prevalence of primary hyperaldosteronizm in moderate to severe hypertension in the Central Europe region. Journal of human hypertension 2003; 17: 349-352. Go to original source... Go to PubMed...
  3. Gordon RD. The challenge of more robust and reproducible methodology in screening for primary aldosteronizm. Journal of hypertension 2004; 22: 251-255. Go to original source... Go to PubMed...
  4. Sawka AM, Young WF, Thompson GB, et al. Primary aldosteronizm: factors associated with normalization of blood pressure after surgery. Annals of internal medicine 2001; 135: 258-261. Go to original source... Go to PubMed...
  5. Conn JW, Knopf RF, Nesbit RM. Clinical Characteristics of Primary Aldosteronizm from an Analysis of 145 Cases. Am J Surg 1964; 107: 159-172. Go to original source... Go to PubMed...
  6. Laragh JH. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. The American journal of medicine 1973; 55: 261-274. Go to original source... Go to PubMed...
  7. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002; 970: 89-100. Go to original source... Go to PubMed...
  8. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney international 2004; 66: 1-9. Go to original source... Go to PubMed...
  9. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. The New England journal of medicine 1999; 341: 709-717. Go to original source... Go to PubMed...
  10. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. The New England journal of medicine 2003; 348: 1309-1321. Go to original source... Go to PubMed...
  11. Indra T, Holaj R. Je orgánové postižení u primárního hyperaldosteronizmu častější než u esenciální hypertenze? Cor et vasa: časopis České kardiologické společnosti 2011; 53: 449-453. Go to original source...
  12. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-1810. Go to original source... Go to PubMed...
  13. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865. Go to original source... Go to PubMed...
  14. Neves MF, Amiri F, Virdis A, Diep QN, Schiffrin EL. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy. Can J Physiol Pharmacol 2005; 83: 999-1006. Go to original source... Go to PubMed...
  15. Funder JW. Mineralocorticoid receptor activation and oxidative stress. Hypertension 2007; 50: 840-841. Go to original source... Go to PubMed...
  16. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond) 2007; 113: 267-278. Go to original source... Go to PubMed...
  17. Muiesan ML, Salvetti M, Paini A, et al. Inappropriate left ventricular mass in patients with primary aldosteronizm. Hypertension 2008; 52: 529-534. Go to original source... Go to PubMed...
  18. Catena C, Colussi G, Nadalini E, et al. Cardiovascular Outcomes in Patients With Primary Aldosteronizm After Treatment. Archives of internal medicine 2008; 168: 80-85. Go to original source... Go to PubMed...
  19. Rossi GP, Sacchetto A, Pavan E, et al. Remodeling of the Left Ventricle in Primary Aldosteronizm Due to Conn's Adenoma. Circulation 1997; 95: 1471-1478. Go to original source... Go to PubMed...
  20. Shigematsu Y, Hamada M, Okayama H, et al. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronizm. Hypertension 1997; 29: 723-727. Go to original source... Go to PubMed...
  21. Rizzoni D, Paiardi S, Rodella L, et al. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronizm. The Journal of clinical endocrinology and metabolism 2006; 91: 2638-2642. Go to original source... Go to PubMed...
  22. Štrauch B, Petrák O, Wichterle D, Zelinka T, Holaj R, Widimský J, Jr. Increased arterial wall stiffness in primary aldosteronizm in comparison with essential hypertension. Am J Hypertens 2006; 19: 909-914. Go to original source... Go to PubMed...
  23. Holaj R, Zelinka T, Wichterle D, Petrák O, Štrauch B, Widimský J, Jr. Increased intima-media thickness of the common carotid artery in primary aldosteronizm in comparison with essential hypertension. Journal of hypertension 2007; 25: 1451-1457. Go to original source... Go to PubMed...
  24. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000; 32: 865-879. Go to original source... Go to PubMed...
  25. Rossi GP, Di Bello V, Ganzaroli C, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronizm. Hypertension 2002; 40: 23-27. Go to original source... Go to PubMed...
  26. Ahmed SH, Husain NM, Khawaja SN, Massey CV, Pettyjohn FS. Is primary hyperaldosteronizm a risk factor for aortic dissection? Cardiology 2007; 108: 48-50. Go to original source... Go to PubMed...
  27. Meszaros I, Morocz J, Szlavi J, et al. Epidemiology and clinicopathology of aortic dissection. Chest 2000; 117: 1271-1278. Go to original source... Go to PubMed...
  28. Indra T, Holaj R, Zelinka T, et al. Left ventricle remodeling in men with moderate to severe volume-dependent hypertension. J Renin Angiotensin Aldosterone Syst 2012; 13: 426-434. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.